ArticleJournal for immunotherapy of cancer2019

Safety and enhanced immunostimulatory activity of the DRD2 antagonist ONC201 in advanced solid tumor patients with weekly oral administration.

Mark N Stein et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.